Enlarge (credit: Diamond Shruumz )

Newly released testing data of Diamond Shruumz-brand gummies purchased in 2023 identified the presence of psilocin, a hallucinogenic drug closely related to the magic-mushroom drug psilocybin that is classified as a Schedule I drug, alongside psilocybin, heroin, and LSD.

The finding comes as Diamond Shruumz's current line of gummies, chocolates, and candy cones is being recalled and are under active investigation in connection to a nationwide rash of severe illnesses, which have involved seizures, intubation, and intensive care. As of the latest update on July 15, 69 people in 28 states have been sickened after eating a Diamond Shruumz product. Sixty of the 69 sought medical care, 36 were hospitalized, and there is one potentially associated death under investigation.

The new finding of psilocin in the products, published by researchers at the University of Virginia, adds to growing concern about psychedelic mushroom candies generally. Although the candies are marketed as being legal, they have often been found to contain various undisclosed illegal drugs, gray market synthetic versions of drugs, as well as dangerous adulterants and contaminants.

Enlarge / The Birthday Cake flavored bar.

One person may have died from eating Diamond Shruumz microdosing candies, which were recalled last week amid a rash of severe illnesses involving seizures, intubation, and intensive care stays .

According to an update this week from the Food and Drug Administration , the cluster of cases continues to increase across the country. To date, 48 people across 24 states have fallen ill after eating the candies, which include chocolate bars, gummies, and candy cones that were sold online and in retail locations, such as smoke and vape shops. Of the 48 people sickened, 46 were ill enough to seek medical care, and 27 were admitted to a hospital.

For now, the death noted in the FDA's latest update is only "potentially associated" with the candies and is still under investigation. No other information is yet available.

Enlarge (credit: SEAN GLADWELL )

Unraveling how consciousness arises out of particular configurations of organic matter is a quest that has absorbed scientists and philosophers for ages. Now, with AI systems behaving in strikingly conscious-looking ways, it is more important than ever to get a handle on who and what is capable of experiencing life on a conscious level. As Christof Koch writes in Then I Am Myself the World , "That you are intimately acquainted with the way life feels is a brute fact about the world that cries out for an explanation." His explanation—bounded by the limits of current research and framed through Koch’s preferred theory of consciousness—is what he eloquently attempts to deliver.

Koch, a physicist, neuroscientist, and former president of the Allen Institute for Brain Science, has spent his career hunting for the seat of consciousness, scouring the brain for physical footprints of subjective experience. It turns out that the posterior hot zone, a region in the back of the neocortex, is intricately connected to self-awareness and experiences of sound, sight, and touch. Dense networks of neocortical neurons in this area connect in a looped configuration; output signals feedback into input neurons, allowing the posterior hot zone to influence its own behavior. And herein, Koch claims, lies the key to consciousness.

In the hot zone

According to integrated information theory (IIT)—which Koch strongly favors over a multitude of contending theories of consciousness—the Rosetta Stone of subjective experience is the ability of a system to influence itself: to use its past state to affect its present state and its present state to influence its future state.

Enlarge / Girl with an ecstasy tablet on her tongue. (credit: Getty | UniversalImagesGroup )

A corporation dedicated to studying the benefits of psychedelic drugs filed an application with the Food and Drug Administration this week for approval to use MDMA—aka ecstasy or molly—in combination with talk therapy to treat post-traumatic stress disorder.

If approved, it would be the first-of-its-kind combination treatment—a psychedelic-assisted therapy. An approval would also require the Drug Enforcement Administration to reclassify MDMA, which is currently in the DEA's most restricted category, Schedule I, which is defined as drugs "with no currently accepted medical use and a high potential for abuse." The category also includes LSD, heroin, and marijuana.

The public benefit corporation (PBC) that filed the FDA application was created by MAPS, The Multidisciplinary Association for Psychedelic Studies, which has been supporting this type of work since 1986. The application is based on positive data from two randomized, double-blind, placebo-controlled Phase III studies, which were funded and organized by MAPS and MAPS PBC.

Enlarge / New research hints at how psychedelics can trigger rapid, lasting change. (credit: wildpixel/Getty Images )

The human brain can change —but usually only slowly and with great effort, such as when learning a new sport or foreign language, or recovering from a stroke. Learning new skills correlates with changes in the brain , as evidenced by neuroscience research with animals and functional brain scans in people. Presumably, if you master Calculus 1, something is now different in your brain. Furthermore, motor neurons in the brain expand and contract depending on how often they are exercised— a neuronal reflection of “use it or lose it.”

People may wish their brains could change faster—not just when learning new skills, but also when overcoming problems like anxiety, depression, and addictions.

Clinicians and scientists know there are times the brain can make rapid, enduring changes. Most often, these occur in the context of traumatic experiences , leaving an indelible imprint on the brain.

Enlarge (credit: VICTOR de SCHWANBERG/SCIENCE PHOTO LIBRARY )

Psychedelic drugs are often used for entertainment purposes. But there have been some recent indications that they can be effective against PTSD and treatment-resistant depression. Figuring out whether these substances work as medicinal drugs can be challenging because (as one researcher helpfully pointed out) it's difficult to do a controlled experiment when it's easy to figure out who's in the treatment group. Still, we've made some progress in understanding what's happening with psychedelics at the molecular level.

Many psychedelics seem to bind to a specific receptor for the neural signaling molecule serotonin, activating it. That would seem to make sense for antidepressive effects, given that many popular antidepressants also alter serotonin signaling (such as in SSRIs, or selective serotonin reuptake inhibitors). But SSRIs don't produce any of the mind-altering effects that drive non-medical interest in psychedelics, so things remain a bit confusing.

New data suggests that psychedelics may activate serotonin signaling in a very different way than serotonin itself can, reaching the receptors in parts of the cell that serotonin can't get to.